298 related articles for article (PubMed ID: 36758067)
1. Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.
Sandberg JT; Löfling M; Varnaitė R; Emgård J; Al-Tawil N; Lindquist L; Gredmark-Russ S; Klingström J; Loré K; Blom K; Ljunggren HG
PLoS Negl Trop Dis; 2023 Feb; 17(2):e0010616. PubMed ID: 36758067
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
[TBL] [Abstract][Full Text] [Related]
3. Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice.
Wang HJ; Li XF; Ye Q; Li SH; Deng YQ; Zhao H; Xu YP; Ma J; Qin ED; Qin CF
Vaccine; 2014 Feb; 32(8):949-56. PubMed ID: 24394443
[TBL] [Abstract][Full Text] [Related]
4. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
[TBL] [Abstract][Full Text] [Related]
5. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.
Domnich A; Panatto D; Arbuzova EK; Signori A; Avio U; Gasparini R; Amicizia D
Hum Vaccin Immunother; 2014; 10(10):2819-33. PubMed ID: 25483679
[TBL] [Abstract][Full Text] [Related]
8. Stable and Highly Immunogenic MicroRNA-Targeted Single-Dose Live Attenuated Vaccine Candidate against Tick-Borne Encephalitis Constructed Using Genetic Backbone of Langat Virus.
Tsetsarkin KA; Maximova OA; Liu G; Kenney H; Teterina NL; Pletnev AG
mBio; 2019 Apr; 10(2):. PubMed ID: 31015334
[TBL] [Abstract][Full Text] [Related]
9. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
10. Flavivirus-induced antibody cross-reactivity.
Mansfield KL; Horton DL; Johnson N; Li L; Barrett ADT; Smith DJ; Galbraith SE; Solomon T; Fooks AR
J Gen Virol; 2011 Dec; 92(Pt 12):2821-2829. PubMed ID: 21900425
[TBL] [Abstract][Full Text] [Related]
11. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine.
Li Y; Merbah M; Wollen-Roberts S; Beckman B; Mdluli T; Curtis DJ; Currier JR; Mendez-Rivera L; Dussupt V; Krebs SJ; De La Barrera R; Michael NL; Paquin-Proulx D; Eller MA; Koren MA; Modjarrad K; Rolland M
EBioMedicine; 2023 Nov; 97():104815. PubMed ID: 37793212
[TBL] [Abstract][Full Text] [Related]
12. Protection of swine by potent neutralizing anti-Japanese encephalitis virus monoclonal antibodies derived from vaccination.
Young CL; Lyons AC; Hsu WW; Vanlandingham DL; Park SL; Bilyeu AN; Ayers VB; Hettenbach SM; Zelenka AM; Cool KR; Peterson GJ; Higgs S; Huang YS
Antiviral Res; 2020 Feb; 174():104675. PubMed ID: 31825852
[TBL] [Abstract][Full Text] [Related]
13. Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.
Turtle L; Tatullo F; Bali T; Ravi V; Soni M; Chan S; Chib S; Venkataswamy MM; Fadnis P; Yaïch M; Fernandez S; Klenerman P; Satchidanandam V; Solomon T
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005263. PubMed ID: 28135273
[TBL] [Abstract][Full Text] [Related]
14. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB; Vrati S
Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.
Wright PF; Ankrah S; Henderson SE; Durbin AP; Speicher J; Whitehead SS; Murphy BR; Pletnev AG
Vaccine; 2008 Feb; 26(7):882-90. PubMed ID: 18207289
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review.
Li X; Ma SJ; Liu X; Jiang LN; Zhou JH; Xiong YQ; Ding H; Chen Q
Hum Vaccin Immunother; 2014; 10(12):3579-93. PubMed ID: 25668666
[TBL] [Abstract][Full Text] [Related]
17. Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis.
Wang SY; Cheng XH; Li JX; Li XY; Zhu FC; Liu P
Hum Vaccin Immunother; 2015; 11(6):1418-25. PubMed ID: 25915588
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine.
Lima NS; Moon D; Darko S; De La Barrera RA; Lin L; Koren MA; Jarman RG; Eckels KH; Thomas SJ; Michael NL; Modjarrad K; Douek DC; Trautmann L
Front Immunol; 2021; 12():640190. PubMed ID: 33717194
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
Arroyo J; Guirakhoo F; Fenner S; Zhang ZX; Monath TP; Chambers TJ
J Virol; 2001 Jan; 75(2):934-42. PubMed ID: 11134306
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
Li Y; Chu SY; Yue C; Wannemuehler K; Xie S; Zhang F; Wang Y; Zhang Y; Ma R; Li Y; Zuo Z; Rodewald L; Xiao Q; Feng Z; Wang H; An Z
Lancet Infect Dis; 2019 Apr; 19(4):402-409. PubMed ID: 30833160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
